UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.  20549

 
FORM 8-K
 

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): May 15, 2018

Zoetis Inc.
(Exact name of registrant as specified in its charter)

Delaware
 
001-35797
 
46-0696167
(State or other jurisdiction
 
(Commission File
 
(I.R.S. Employer
of incorporation)
 
Number)
 
Identification No.)

10 Sylvan Way, Parsippany, New Jersey
 
07054
(Address of principal executive offices)
 
(Zip Code)

(973) 822-7000
(Registrant's telephone number, including area code)



(Former Name or Former Address, if changed since last report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o     Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o     Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o     Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o




Item 5.07. Submission of Matters to a Vote of Security Holders.
On May 15, 2018, Zoetis Inc. (the “Company”) held its Annual Meeting of Shareholders at the Hilton Short Hills located at 41 John F. Kennedy Parkway, Short Hills, New Jersey 07078 (the “Annual Meeting”). At the Annual Meeting, the Company’s shareholders voted on three proposals, each of which is described in more detail in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on April 2, 2018 (the “Proxy Statement”). There were 429,377,640 shares of common stock present at the Annual Meeting in person or by proxy, which represented 88.5% of the voting power of the shares of common stock entitled to vote at the Annual Meeting, and which constituted a quorum for the transaction of business. Holders of the Company’s common stock were entitled to one vote for each share held as of the close of business on March 21, 2018 (the “Record Date”).
The shareholders of the Company voted on the following proposals at the Annual Meeting:
1. To elect four directors, all of whom are currently serving on the Company’s Board of Directors, each to serve until the 2021 Annual Meeting of Shareholders or until his or her successor has been elected and qualified, or until his or her earlier death, resignation or removal.
2. A non-binding advisory vote on the compensation program for the Company’s named executive officers as disclosed in the Proxy Statement.
3. To ratify the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2018.
The voting results for each of these proposals are detailed below.

1. Election of Directors
Nominee
Votes For
Votes Against
Abstentions
Broker Non-Votes
Sanjay Khosla
402,699,341
2,787,191
1,251,055
22,640,053
Willie M. Reed
401,934,971
3,552,630
1,249,986
22,640,053
Linda Rhodes
403,483,477
3,116,836
137,274
22,640,053
William C. Steere, Jr.
401,271,762
4,209,776
1,256,049
22,640,053
Each of the four nominees for director was elected to serve until the 2021 Annual Meeting of Shareholders or until his or her successor has been elected and qualified, or until his or her earlier death, resignation or removal.

2. Advisory Vote on Executive Compensation
Votes For
Votes Against
Abstentions
Broker Non-Votes
393,980,446
12,372,706
384,435
22,640,053
The shareholders approved, on a non-binding advisory basis, the compensation program for the Company’s named executive officers as disclosed in the Proxy Statement.

3. Ratification of Appointment of Independent Registered Public Accounting Firm
Votes For
Votes Against
Abstentions
Broker Non-Votes
427,664,411
1,489,199
224,030
The shareholders ratified the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2018.




Item 7.01. Regulation FD Disclosure.
On May 15, 2018, the Company declared a dividend of $0.126 per share for the third quarter of 2018. The dividend will be paid on September 4, 2018, to all holders of record of the Company's common stock as of the close of business on July 20, 2018.

Item 9.01. Financial Statements and Exhibits.
(d)
Exhibits:
 
 
99.1
Press Release issued on May 15, 2018.




SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
ZOETIS INC.
 
 
By:
 
/s/ Heidi C. Chen
Name:
 
Heidi C. Chen
Title:
 
Executive Vice President,
 
 
General Counsel and Corporate Secretary
Dated: May 15, 2018






INDEX OF EXHIBITS
 
Exhibit
 
 
Number
 
Description
 
 
 
 
Press Release issued on May 15, 2018.


Exhibit 99.1
ZOETISCA02A03A02A02A23.JPG


FOR IMMEDIATE RELEASE:             
May 15, 2018
Media Contacts :
 
Investor Contact :
Elinore White
 
Steve Frank
1-973-443-2835 (o)
 
1-973-822-7141 (o)
elinore.y.white@zoetis.com
 
steve.frank@zoetis.com
 
 
 
Kristen Seely
 
 
1-973-443-2777 (o)
 
 
kristen.seely@zoetis.com
 
 

Zoetis Declares Third Quarter 2018 Dividend

PARSIPPANY, N.J. - May 15, 2018 - The Board of Directors of Zoetis Inc . (NYSE:ZTS) has declared a third quarter 2018 dividend payable to holders of the company’s common stock of $0.126 per share. The dividend is to be paid on Tuesday, Sept. 4, 2018, to holders of record on Friday, July 20, 2018.

About Zoetis
Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products, genetic tests, biodevices and a range of services. Zoetis serves veterinarians, livestock producers and people who raise and care for farm and companion animals with sales of its products in more than 100 countries. In 2017, the company generated annual revenue of $5.3 billion with approximately 9,000 employees. For more information, visit www.zoetis.com .

DISCLOSURE NOTICES
Forward-Looking Statements: This press release contains forward-looking statements, which reflect the current views of Zoetis with respect to business plans or prospects, future operating or financial performance, future use of cash and dividend payments, and other future events. These statements are not guarantees of future performance or actions. Forward-looking statements are subject to risks and uncertainties. If one or more of these risks or uncertainties materialize, or if management's underlying assumptions prove to be incorrect, actual results may differ materially from those contemplated by a forward-looking statement. Forward-looking statements speak only as of the date on which they are made. Zoetis expressly disclaims any obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. A further list and description of risks, uncertainties and





other matters can be found in our Annual Report on Form 10-K for the fiscal year ended December 31, 2017, including in the sections thereof captioned “Forward-Looking Statements and Factors That May Affect Future Results” and “Item 1A. Risk Factors,” in our Quarterly Reports on Form 10-Q and in our Current Reports on Form 8-K. These filings and subsequent filings are available online at www.sec.gov, www.zoetis.com, or on request from Zoetis.

###